193 related articles for article (PubMed ID: 30412596)
21. Are Office-Based Workplace Interventions Designed to Reduce Sitting Time Cost-Effective Primary Prevention Measures for Cardiovascular Disease? A Systematic Review and Modelled Economic Evaluation.
Gao L; Nguyen P; Dunstan D; Moodie M
Int J Environ Res Public Health; 2019 Mar; 16(5):. PubMed ID: 30866495
[TBL] [Abstract][Full Text] [Related]
22. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.
Lam SW; Wai M; Lau JE; McNamara M; Earl M; Udeh B
Pharmacotherapy; 2017 Jan; 37(1):94-103. PubMed ID: 27870079
[TBL] [Abstract][Full Text] [Related]
23. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
24. Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal Practice.
Elliott RA; Tanajewski L; Gkountouras G; Avery AJ; Barber N; Mehta R; Boyd MJ; Latif A; Chuter A; Waring J
Pharmacoeconomics; 2017 Dec; 35(12):1237-1255. PubMed ID: 28776320
[TBL] [Abstract][Full Text] [Related]
25. Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Health Technology Assessment.
Health Quality Ontario
Ont Health Technol Assess Ser; 2019; 19(6):1-199. PubMed ID: 30873251
[TBL] [Abstract][Full Text] [Related]
26. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
27. Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model.
Moise N; Huang C; Rodgers A; Kohli-Lynch CN; Tzong KY; Coxson PG; Bibbins-Domingo K; Goldman L; Moran AE
Hypertension; 2016 Jul; 68(1):88-96. PubMed ID: 27181996
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of a complex intervention in general practice to increase uptake of long-acting reversible contraceptives in Australia.
Lewandowska M; De Abreu Lourenco R; Haas M; Watson CJ; Black KI; Taft A; Lucke J; McGeechan K; McNamee K; Peipert JF; Mazza D
Aust Health Rev; 2021 Dec; 45(6):728-734. PubMed ID: 34903325
[TBL] [Abstract][Full Text] [Related]
29. The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction.
Ademi Z; Ofori-Asenso R; Zomer E; Owen A; Liew D
Eur J Prev Cardiol; 2021 Jul; 28(8):897-904. PubMed ID: 34298556
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of Mediterranean diet and physical activity in secondary CVD prevention: results from the UCC-SMART cohort study.
Bonekamp NE; Visseren FLJ; van der Schouw YT; van der Meer MG; Teraa M; Ruigrok Y; Geleijnse JM; Koopal C;
Eur J Prev Cardiol; 2024 Mar; ():. PubMed ID: 38547043
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis.
Howard K; White S; Salkeld G; McDonald S; Craig JC; Chadban S; Cass A
Value Health; 2010; 13(2):196-208. PubMed ID: 19878493
[TBL] [Abstract][Full Text] [Related]
32. Estimated health benefits, costs, and cost-effectiveness of eliminating industrial trans-fatty acids in Australia: A modelling study.
Marklund M; Zheng M; Veerman JL; Wu JHY
PLoS Med; 2020 Nov; 17(11):e1003407. PubMed ID: 33137090
[TBL] [Abstract][Full Text] [Related]
33. The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective.
Zomer E; Liew D; Tonkin A; Trauer JM; Ademi Z
Int J Cardiol; 2019 Jun; 285():1-5. PubMed ID: 30686493
[TBL] [Abstract][Full Text] [Related]
34. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.
Buxton M; Caine N; Chase D; Connelly D; Grace A; Jackson C; Parkes J; Sharples L
Health Technol Assess; 2006 Aug; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046
[TBL] [Abstract][Full Text] [Related]
35. A systematic review and economic evaluation of exercise referral schemes in primary care: a short report.
Campbell F; Holmes M; Everson-Hock E; Davis S; Buckley Woods H; Anokye N; Tappenden P; Kaltenthaler E
Health Technol Assess; 2015 Jul; 19(60):1-110. PubMed ID: 26222987
[TBL] [Abstract][Full Text] [Related]
36. Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly.
Lin L; Teng M; Zhao YJ; Khoo AL; Seet RC; Yong QW; Yeo TC; Lim BP
Cardiovasc Drugs Ther; 2015 Apr; 29(2):187-97. PubMed ID: 25860556
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of the diabetes care protocol, a multifaceted computerized decision support diabetes management intervention that reduces cardiovascular risk.
Cleveringa FG; Welsing PM; van den Donk M; Gorter KJ; Niessen LW; Rutten GE; Redekop WK
Diabetes Care; 2010 Feb; 33(2):258-63. PubMed ID: 19933991
[TBL] [Abstract][Full Text] [Related]
38. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP
J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
[TBL] [Abstract][Full Text] [Related]
39. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia.
Cohen N; Minshall ME; Sharon-Nash L; Zakrzewska K; Valentine WJ; Palmer AJ
Pharmacoeconomics; 2007; 25(10):881-97. PubMed ID: 17887808
[TBL] [Abstract][Full Text] [Related]
40. Screening for Asymptomatic Coronary Artery Disease in Waitlisted Kidney Transplant Candidates: A Cost-Utility Analysis.
Ying T; Tran A; Webster AC; Klarenbach SW; Gill J; Chadban S; Morton R
Am J Kidney Dis; 2020 May; 75(5):693-704. PubMed ID: 31810731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
